Beste apotheek van Nederland

McMahon C G. An attempt to standardize the pharmacological
diagnostic screening of vasculogenic impotence with
prostaglandin E1. Int J Impot Res 1995;7(2):83-90.
McMahon C G. Topiglan: MacroChem. Curr Opin Investig
Drugs 2002;3(4):602-606.
McMahon C G. A pilot study of the role of intracavernous
injection of vasoactive intestinal peptide (VIP) and
phentolamine mesylate in the treatment of erectile dysfunction.
Int J Impot Res 1996;8(4):233-236.
McMahon C G. Priapism associated with concurrent use of
phosphodiesterase inhibitor drugs and intracavernous injection
therapy. Int J Impot Res 2003;15(5):383-384.
McMahon C G, Samali R, Johnson H. Efficacy, safety and
patient acceptance of sildenafil citrate as treatment for erectile
dysfunction. Br J Urol 2000;164(4):1192-1196.
McMahon C G, Samali R, Johnson H. Treatment of
intracorporeal injection nonresponse with sildenafil alone or in
combination with triple agent intracorporeal injection therapy.
Br J Urol 1997;162(6):1992-1997.
McMahon C, Lording D, Stuckey B et al. Vardenafil improved
erectile function in a "real-life" broad population study of men
with moderate to severe erectile dysfunction in Australia and
New Zealand. Br J Sex Med 2006;3(5):892-900.
McVary K T, Polepalle S, Riggi S et al. Topical prostaglandin
E1 SEPA gel for the treatment of erectile dysfunction.. Br J Urol
1999;162(3 Pt 1):732
Mealy N E. Alprostadil cream. Drugs of the Future
2004;29(6):626-627.
Mealy N E, Bayes M. PT-141. Drugs of the Future
2004;29(11):1177
Mehdiyev T V. Intracavernous injection probe of vasoactive
preparations in the diagnosis of erectile dysfunctions in patients
with diabetes mellitus. Azerbaidzhanskii Meditsinskii Zhurnal
2002;(pp 17-19):-19.
Meinhardt W, de la, Fuente R B et al. Prostaglandin E1 with
phentolamine for the treatment of erectile dysfunction. Int J
Impot Res 1996;8(1):5-7.
Meinhardt W, Nijeholt A A, Kropman R F et al. Comparison of
a mixture of papaverine, phentolamine and prostaglandin E1
with other intracavernous injections. Eur Urol 1994;26(4):319­
321.
Mellinger B C, Fried J J, Darracott Vaughan. Papaverineinduced
penile blood flow acceleration in impotent men
measured by duplex scanning. Br J Urol 1990;144(4):897-899.
Merrick G S, Butler W M, Lief J H et al. Efficacy of sildenafil
citrate in prostate brachytherapy patients with erectile
dysfunction. Urology 1999;53(6):1112-1116.
Metawea B, El-Nashar A R, Gad-Allah A et al.
Intracavernous papaverine/phentolamine-induced
priapism can be accurately predicted with color
Doppler ultrasonography. Urology 2005;66(4):858­
860.
Meyhoff H H, Rosenkilde P, Bodker A. Non-invasive
management of impotence with transcutaneous
nitroglycerin. Br J Urol 1992;69(1):88-90.
Mikhail N. Does Testosterone Have a Role in Erectile
Function?. Am J Med 2006;119373-382.
Millard R J, Stricker P D, Lynch W J et al. Risks of
self-injection therapy for impotence. Med J Aust
1996;165(2):117-118.
Miller N, Smolkin M E, Bissonette E et al.
Undetectable prostate specific antigen at 6-12 months:
a new marker for early success in hormonally treated
patients after prostate brachytherapy. Cancer
2005;103(12):2499-2506.
Mills T M, Lewis R W. The role of androgens in the
erectile response: A 1999 perspective. Mol Urol
1999;3(2):75-80.
Mirone V G, Stief C G. Efficacy of apomorphine SL
in erectile dysfunction.[erratum appears in BJU Int
2002 Jan;89(1):140]. [Review] [11 refs]. BJU Int
2001;88(Suppl 3):25-29.
Mirone V, Imbimbo C, Fabrizio F et al. Ketanserin
plus prostaglandin E1 (PGE-1) as intracavernosal
therapy for patients with erectile dysfunction
unresponsive to PGE-1 alone. Br J Urol
1996;77(5):736-739.
Mirone V, Palmieri A, Cucinotta D et al. Flexibledose
vardenafil in a community-based population of
men affected by erectile dysfunction: a 12-week openlabel,
multicenter trial. Br J Sex Med 2005;2(6):842­
847.
Mittleman M A, Glasser D B, Orazem J. Clinical trials
of sildenafil citrate (Viagra) demonstrate no increase
in risk of myocardial infarction and cardiovascular
death compared with placebo. Int J Clin Pract
2003;57(7):597-600.
Mittleman M A, Maclure M, Glasser D B. Evaluation
of acute risk for myocardial infarction in men treated
with sildenafil citrate. Am J Cardiol 2005;96(3):443­
446.
Moemen M N, Hamed H A, Kamel I I et al. Clinical
and sonographic assessment of the side effects of
intracavernous injection of vasoactive substances. Int J
Impot Res 2004;16(2):143-145.
D-113